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Abstract
The cyanide metabolite 2-aminothiazoline-4-carboxylic acid (ATCA) is a promising biomarker for cyanide exposure because of its stability
and the limitations of direct determination of cyanide and more abundant cyanide metabolites. A simple, sensitive, and specific method
based on derivatization and subsequent gas chromatography–mass spectrometry (GC–MS) analysis was developed for the identification and
quantification of ATCA in synthetic urine and swine plasma. The urine and plasma samples were spiked with an internal standard (ATCA-d2),
diluted, and acidified. The resulting solution was subjected to solid phase extraction on a mixed-mode cation exchange column. After elution
and evaporation of the solvent, a silylating agent was used to derivatize the ATCA. Quantification of the derivatized ATCA was accomplished
on a gas chromatograph with a mass selective detector. The current method produced a coefficient of variation of less than 6% (intra- and
interassay) for two sets of quality control (QC) standards and a detection limit of 25 ng/ml. The applicability of the method was evaluated by
determination of elevated levels of ATCA in human urine of smokers in relation to non-smokers for both males and females.
© 2005 Elsevier B.V. All rights reserved.
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1. Introduction
Exposure to cyanide can occur by a number of scenar-
ios, including the use of cyanide as a chemical warfare agent
(CWA) [1–5]. The analysis of biological matrices, specifi-
cally urine and blood, to verify exposure to cyanide is im-
portant to determine past exposure to cyanide [1,5]. Due
to its volatility, hydrogen cyanide rapidly dissipates from
open areas. Therefore, biological fluids of persons or ani-
mals exposed to hydrogen cyanide may be the only repos-
itory of evidence that cyanide was used as a CWA. As
∗ Corresponding author. Tel.: +1 605 688 6698; fax: +1 605 688 6364.
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seen in Fig. 1, three major markers of cyanide exposure ap-
pear in the blood or urine of exposed individuals: cyanide
ion (CN−), thiocyanate (SCN−), and 2-aminothiazoline-4-
carboxylic acid (ATCA) or its tautomer 2-iminothiazolidine-
4-carboxylic acid (ITCA).
Although many sensitive methods exist for analysis of
cyanide ion [6], they all suffer from the practical limita-
tions that stem from cyanide’s volatility and nucleophilic na-
ture. Under normal physiological conditions, cyanide (pKa
9.2) is protonated. This protonated form of cyanide is ex-
tremely volatile [5,7], which contributes to its elimination
from analytical samples. The nucleophilic nature of the non-
protonated form of cyanide also contributes to its elimination
from biological media. Therefore, depending on the route
1570-0232/$ – see front matter © 2005 Elsevier B.V. All rights reserved.
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Fig. 1. Cyanide metabolism and major modes of release. Adapted from
Baskin et al. [6]. A proposed mechanism for the formation of ATCA from
the reaction of cyanide with cystine is presented by Nagasawa et al. [16].
and duration of exposure, cyanide is typically eliminated
from blood within 20 min post-exposure [5,7,8]. In addi-
tion to rapidly decreasing concentrations in biological fluids,
cyanide sometimes forms as an artifact of storage conditions
in a variety of biological samples, including blood [9–11].
Cyanide exhibits variable concentrations in biological fluids
depending on the route of exposure (e.g., oral versus inhala-
tion) [12] and has significant endogenous (inherently present)
concentrations. Some sources of endogenous cyanide include
normal metabolism of amino acids within the body along with
external sources such as smoking, inhalation of smoke from
fires, and some types of food [5]. Because of these limitations,
analytical determination of cyanide metabolites is generally
more advantageous to direct cyanide determination. It should
be noted that the metabolites of cyanide should also exhibit
significant endogenous concentrations, originating from the
same sources of endogenous cyanide.
Thiocyanate is the major metabolite of cyanide, and a
number of sensitive methods are available for its measure-
ment in biological fluids [6]. Thiocyanate has many advan-
tages as a marker for cyanide exposure. It is non-volatile
and can be analyzed in blood, urine, and saliva. However,
thiocyanate does have some disadvantages as an indicator of
cyanide exposure. Ballantyne [10] found that analytical re-
covery of thiocyanate from whole blood is not quantitative
and thiocyanate concentrations in blood varied inconsistently
during storage at various temperatures over a period of 2
weeks. Isom and Baskin [13] also noted that thiocyanate may
be formed by other modes of metabolism besides cyanide in-
toxication or metabolism.
While there are numerous sensitive analytical techniques
to determine both cyanide and thiocyanate in biological flu-
ids, very few techniques exist to analyze for ATCA. In fact, the
liquid chromatographic analytical technique of Lundquist et
al. [14] and the spectrophotometric method of Wood et al. [15]
are the only available methods for determination of ATCA in
biological fluids. ATCA accounts for approximately 20% of
cyanide metabolism and increases as exposure increases [5].
ATCA is formed when cyanide reacts with l-cystine through
a proposed intermediate, -thiocyanoalanine, that is subse-
quently transformed to ATCA (Fig. 1) [16]. ATCA may be
present as a tautomer between itself and 2-iminothiazolidine-
4-carboxylic acid (ITCA). The structure of ATCA resembles
a cyclic amino acid and appears to have the same general
properties as an amino acid with similar functional groups.
ATCA may be an excellent marker for indicating cyanide ex-
posure primarily because of its stability. It is stable for months
in biological samples at freezing and ambient temperatures
[14]. The structure of ATCA also lends itself to simple but
extremely effective sample preparation and derivatization.
ATCA represents an alternative metabolite of cyanide ex-
posure, and a simple assay for ATCA may circumvent the dis-
advantages of cyanide and thiocyanate analysis. Therefore,
the objective of this study was to develop a novel analyti-
cal method to determine ATCA concentrations in urine and
plasma for the purpose of simple and accurate verification of
exposure to cyanide.
2. Experimental
2.1. Reagents and standards
All chemicals and solvents were at least HPLC grade.
ATCA (l-2-aminothiazoline-4-carboxylic acid) was obtained
from Chem-Impex International (Wood Dale, IL, USA). A
standard stock solution (100g/ml) was prepared in 0.1 M
HC1 and used throughout the current study. An aqueous am-
monium hydroxide solution (approximately 50%) was used
to prepare elution solvents. Oasis® MCX (mixed-mode cation
exchange) columns were obtained from Waters Corporation
(Milford, MA, USA). The derivatizing agent N-methyl-N-
trimethylsilyl-trifluoroacetamide (MSTFA) was purchased
from Pierce Chemical Company (Rockford, IL, USA). All
solvents were purchased from Sigma–Aldrich (St. Louis,
MO, USA). Deuterated ATCA (ATCA-d2) was obtained from
the lab of Dr. Herbert T. Nagasawa (Department of Veterans
Affairs Medical Center, Minneapolis, MN, USA) prepared
by reaction of deuterated l-cysteine (3,3-d2) with cyanamide
[16].
2.2. Biological fluids
Synthetic urine and swine (Sus scrofa) plasma were used
to optimize analytical methodologies and sample prepara-
tion techniques. The use of synthetic urine as a sample matrix
was necessary due to endogenous concentrations of ATCA in
urine. The synthetic urine was prepared as a 1 kg stock solu-
tion according to Inn et al. [17] with chemicals obtained from
Sigma–Aldrich (St. Louis, MO, USA), TCI (Tokyo Chemi-
cal International, Tokyo, Japan), and Acros Organics (Mor-
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ris Plains, NJ, USA). Swine plasma (non-sterile with EDTA
anti-coagulant) was purchased from Pel-Freez Biologicals
(Rogers, AR, USA).
Urine and blood samples from human (Homo sapiens)
subjects, age 21–50 years, were used to evaluate the appli-
cability of the analytical method. Urine samples were used
to determine if a significant difference in ATCA concentra-
tion could be found in the urine of smokers relative to non-
smokers. Smokers consume small amounts of cyanide from
the inhalation of cigarette smoke. Therefore, ATCA concen-
trations in the urine of smokers should be elevated relative
to non-smokers. The number of samples used for this study
totaled 40 with 23 males and 17 females. Volunteers donated
urine in the morning in sterile urinalysis cups that were sub-
sequently stored at 4 ◦C until analyzed. All samples were
analyzed less than 14 days after they were gathered. No per-
sonal information was recorded from the volunteer donors
except their gender and whether they were a smoker. Plasma
was obtained from male non-smokers to determine whether
endogenous levels of ATCA could be detected by the cur-
rent method. Plasma from smokers was not analyzed for the
current study.
2.3. Sample preparation
Urine samples were diluted, acidified, and passed through
a mixed-mode cation exchange column to prepare the sam-
ples for gas chromatography–mass spectrometry (GC–MS)
analysis. Specifically, 100L, of sample (spiked synthetic
urine, human urine, spiked swine plasma, or human plasma)
was diluted with 900L of 0.1 M HC1 to ensure the ATCA
was positively charged (pH < 1). ATCA-d2 (100 ng/ml) was
added to the diluted sample as an internal standard. This
diluted sample was then aspirated through an MCX col-
umn, after conditioning with successive washes of 1 ml each
methanol and H2O. The column was then washed succes-
sively with 1 ml each of 0.1 M HC1 and 100% methanol.
The ATCA was eluted from the columns using 1 ml of
CH3OH:NH4OH:H2O (50:25:25) into 2 ml micro-centrifuge
tubes. HC1 (200L of 0.1 M) was added to the centrifuge
tubes to decrease the pH of the sample (pH < 11) prior to dry-
ing (the ring in ATCA may open under heat and basic condi-
tions [14]). The sample was dried completely in a centrifugal
evaporation system (Labconco, Kansas City, MO, USA) at
40 ◦C. The dried samples were derivatized with 150L of
30% MSTFA in hexane for 60 min at 50 ◦C in capped cen-
trifuge tubes to produce the trimethylsilyl (TMS) derivative of
ATCA as illustrated in Fig. 2. The sample was then transferred
with borosilicate transfer pipets to GC–MS autosampler vials
fitted with 200L deactivated glass inserts.
2.4. Gas chromatography–mass spectrometry
Analysis was performed on an Agilent GC–MS system
consisting of a 6890N Series II gas chromatograph, a 5973 se-
ries mass-selective detector, and a 7683 auto-sampler. A DB-
Fig. 2. Derivatization reaction of ATCA with MSTFA. TMS, trimethylsilyl
group Si(CH3)3. Inset: ATCA-d2 chemical structure.
5 MS bonded phase column (30 m× 0.25 mm I.D., 0.25m
film thickness; J&W Scientific, Folsom, CA) was used with
helium as the carrier gas at a flow rate of 0.8 ml/min and col-
umn head pressure of 52.4 kPa (7.6 psi). The auto-sampler
introduced a 1L sample into an injection port with a to-
tal inlet flow of 54 ml/min. The injection port was held at
290 ◦C and contained an Agilent inlet liner of deactivated
borosilicate single-taper with glass wool packing. The purge
flow was initiated at 1 min with a flow of 50 ml/min. The
GC oven temperature was initially held at 100 ◦C for 1 min,
then elevated at a rate of 15 ◦C/min up to 230 ◦C. The gra-
dient was then increased to 30 ◦C/min up to 300 ◦C where
it was held constant for 1 min. This gradient resulted in an
overall run time of 13 min with ATCA-(TMS)3 eluting at ap-
proximately 8.76 min. The GC was interfaced with a mass-
selective detector with the transfer line held at 265 ◦C. Frag-
mentation of the sample was accomplished through electron
impact with selected ion monitoring (SIM) mode for moni-
toring abundant ions of ATCA (m/z 245, 347, and 362) and
ATCA-d2 (m/z 349, and 364) with a dwell time of 100 ms
each. The MS conditions were as follows: ion source pres-
sure 2.0 mPa (1.5× 10−5 Torr), source temperature 230 ◦C,
quadrupole temperature 150 ◦C, electron energy 70 eV, elec-
tron emission current 34.6A, and electron multiplier volt-
age +400 relative to the autotune setting.
2.5. Calibration and quantification
Calibration and quality control (QC) standards were
prepared from the stock ATCA solution in the range of
10–2000 ng/ml by diluting in synthetic urine. Calibration
standards were prepared with concentrations of 10, 20, 50,
100, 200, 500, 1000, and 2000 ng/ml. The 2000 ng/ml stan-
dard was found to be above the upper limit of quantification
(ULOQ) for the method, and the 10 and 20 ng/ml standards
were below the lower limit of quantification (LLOQ). A per-
cent relative standard deviation of less than 10% and a percent
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deviation of less than±20% back-calculated from the nomi-
nal concentration for each calibration standard were used as
criteria for determining the ULOQ, LLOQ, and the linear dy-
namic range. QC standards (n= 5) were prepared at 150 ng/ml
and 800 ng/ml. Intraassay studies were performed by analy-
sis of five replicate QC standards at 150 and 800 ng/ml during
1 day and interassay studies were performed by analysis of
these same quintuplicate QC standards on 3 different days
(within 1 week). The intraassay studies were designed to de-
termine the stability of the method for a single analysis (i.e.,
construct a calibration curve and analyze the QC standards to
validate the method for that analysis). The interassay studies
were designed to evaluate the stability of the method for a
number of days of analysis (i.e., construct three calibration
curves on 3 separate days and analyze the same QC standards
for each calibration curve to validate the method for multiple
analyses).
2.6. ATCA stability
All stability experiments were performed on samples of
1000 ng/ml ATCA in synthetic urine. Short-term stability ex-
periments included evaluation of the stability of ATCA dur-
ing multiple freeze-thaw cycles, stability of ATCA on the
bench-top, and stability of TMS-derivatized ATCA in the
autosampler. Freeze-thaw stability was determined by com-
pleting five freeze-thaw cycles with analysis of ATCA after
each individual cycle. For verification of bench-top stability,
a urine sample was spiked with ATCA and allowed to stand
at room temperature. The spiked sample was analyzed at 0,
1, 2, 4, 8, and 24 h. For the autosampler stability experiment,
eight sets of samples (each in triplicate) were derivatized,
placed in the autosampler, and analyzed at approximately 1,
4, 7, 9, 12, 15, 18, and 20 h post-derivatization to determine
the stability of the TMS derivatized ATCA.
Experiments were also undertaken to determine the long-
term stability of ATCA under typical storage conditions. Five
long-term stability samples were prepared with a range of
normal urinary pH values (4, 6, and 8) [18] and stored at 4,
−20, and −70 ◦C. Three aliquots of these samples were an-
alyzed prior to storage. The samples were then stored for 3
months with analysis at the end of each month. Three repli-
cates of each sample were analyzed for each sampling period.
For example, at the end of the 2nd month, samples were re-
moved from storage and allowed to thaw if necessary, three
aliquots of each sample were removed and analyzed, and the
samples were placed back into storage.
2.7. Assay selectivity and recovery
The selectivity of the assay was determined by comparison
of multiple blank samples of synthetic urine and swine plasma
to determine the potential for interfering (unresolved) back-
ground peaks that co-elute with the ATCA-(TMS)3. To deter-
mine recovery, an aliquot of ATCA was spiked into synthetic
urine or swine plasma for a final concentration of 1000 ng/ml.
The sample was then prepared and analyzed as above. The
recovery of ATCA was calculated as a percentage by dividing
the recovered ATCA concentration by the nominal concen-
tration added to the urine or plasma.
2.8. Data analysis
Calibration was performed by plotting peak area ratios
of the characteristic ions of ATCA (m/z 362) and the inter-
nal standard, ATCA-d2 (m/z 364) as a function of the spiked
ATCA concentration. A weighted (1/x2) linear fit was em-
ployed for all calibration curves. Precision was calculated
as a %CV by dividing the standard deviation of the peak
area ratios by the mean peak area ratio. The accuracy was
calculated as a percentage by dividing the mean calculated
concentration by the intended concentration. Precision and
accuracy were calculated for each set of QC standards (for
intra- and interassay evaluation). Data from long- and short-
term stability experiments were handled by determination of
ATCA concentrations as a percentage of a positive control.
Stability is represented by a percent difference from the pos-
itive control. For the stability experiments, positive controls
were freshly prepared control samples with the same nom-
inal concentration of ATCA as the sample to be analyzed.
Comparison of the urine samples for significant differences
in the ATCA concentrations of smokers compared with non-
smokers was accomplished by a two-tailed t-test. Compar-
ison of the four groups of volunteers (female non-smoker,
female smoker, male non-smoker, and male smoker) was ac-
complished by an analysis of variance and the Bonferroni,
Tukey, and Newman–Keuls multiple range tests to identify
significant differences between the identified subsets of vol-
unteers.
3. Results and discussion
3.1. Sample preparation and GC–MS analysis
ATCA has a basic amine moiety and an acidic carboxylic
acid moiety (Fig. 1). The amine is positively charged at neu-
tral to low pH values and the carboxylic acid is negatively
charged at medium to high pH values. Therefore, either the
amine, the carboxylic acid, or both are charged at all aqueous
pH values. The sample preparation scheme was developed
to take advantage of the positively charged amine at low pH
values. Samples were acidified and mixed-mode cation ex-
change columns were used to electrostatically bind the pos-
itively charged ATCA on the column while allowing neutral
and negatively charged compounds through the column. A
basic solvent was used to neutralize the amine and release it
from the cationic sorbent.
After sample preparation, ATCA must be derivatized to
analyze by GC–MS because it is non-volatile. ATCA was
derivatized with MSTFA, which can react with primary and
secondary amines and carboxylic acid moieties, replacing
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Fig. 3. Electron impact mass spectrum of trimethylsilyl (TMS) derivatized
ATCA and abundant ions. Ions with a mass-to-charge ratio of 245, 347, and
362 were monitored to analyze for ATCA in urine samples. The large 73 m/z
ion above corresponds to one TMS fragment. Inset: Structure of derivatized
ATCA with abundant fragments indicated.
exchangeable hydrogens with TMS groups. Fig. 2 illustrates
the chemical structure of ATCA and the most likely product
of derivatization with MSTFA. Inset is the structure of the
internal standard (ATCA-d2).
Fig. 3 illustrates the mass spectra of derivatized ATCA.
The mass-to-charge ratio of 362 corresponds to the molec-
ular ion of the ATCA-(TMS)3. The probable fragmentation
of the ATCA-(TMS)3 derivative (corresponding to ions 347,
316, and 245 m/z) is also illustrated. Fig. 4 shows a represen-
tative chromatograph of both a blank synthetic urine sample
(0 ng/ml ATCA, lower trace), a spiked synthetic urine sample
(1000 ng/ml ATCA, upper trace), and a human urine sample
(middle trace). Fig. 5 shows a representative chromatograph
of blank human plasma (0 ng/ml ATCA, lower trace) and
a spiked human plasma sample (1000 ng/ml ATCA, upper
trace).
3.2. Linearity and dynamic range
Calibration curves were constructed in the range of
50–1000 ng/ml ATCA with five concentrations, each in trip-
licate, in addition to five blank samples (0 ng/ml ATCA, nom-
inal concentration) for 3 separate days. The data were best
described by a weighted (1/x2) linear least squares fit of the
calibration samples. The best model was determined by anal-
ysis of the weighted sum-of-squares and the absolute relative
error for each model. The dynamic range for the method was
50–1000 ng/ml ATCA, and the limit of detection was found
to be 25 ng/ml with 3 separate days of validation when cal-
culated at a signal-to-noise ratio of 3 (n= 5 for each day).
It should be noted that an internal standard with only two
deuterium atoms may result in overestimation of internal
Fig. 4. Chromatographs of non-spiked synthetic urine (lower trace),
1000 ng/ml ATCA spiked into synthetic urine (upper trace), and non-spiked
human urine (middle trace). The human urine was sampled from a male
non-smoker. The human urine was sampled from a male non-smoker with
a peak area corresponding to an ATCA concentration of 225 ng/ml. The
chromatographs represent the sum of the individual ions gathered in SIM
mode after sample preparation of the urine samples with SPE and derivati-
zation. No internal standard was added to the urine samples prior to analysis.
ATCA-(TMS)3 elutes at approximately 8.76 min.
Fig. 5. Chromatographs of non-spiked human plasma (lower trace) and
spiked human plasma (upper trace). The plasma was sampled from a male
non-smoker. The chromatographs represent the sum of the individual ions
gathered in SIM mode after sample preparation of the urine samples with
SPE and derivatization. No internal standard was added to the plasma sam-
ples prior to analysis. ATCA-(TMS)3 elutes at approximately 8.76 min.
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Table 1
Quality control data for ATCA analysis by GC–MS in synthetic urine
Nominal concentration (ng/ml) Intraassay
accuracy (%)a
Interassay
accuracy (%)b
Intraassay
precision (%CV)a
Interassay
precision (%CV)b
150 105–100 103 <4.1 5.3
800 99.0–97.4 98.0 <3.0 5.8
a Mean of 1 day of validation (n= 5 for each day; overall range is for 3 separate days).
b Mean of 3 days of validation (n= 15).
standard peak areas, particularly when analyte concentrations
are large [19]. This potential problem was accounted for by
developing a calibration curve that excluded calibrators with
a percent deviation of less than±20% from the nominal con-
centration. If the internal standard area is overestimated, the
ratio of analyte to internal standard would decrease, and there-
fore increase the percent deviation of the calibrator from its
nominal concentration. If the overestimation becomes large
enough for a particular concentration, that calibration stan-
dard would be excluded from the curve. For practical pur-
poses, if analyte concentrations are above the ULOQ of the
calibration curve (i.e., overestimation of the internal standard
concentration is occurring), dilution of the sample or use of
a smaller sample volume and reanalysis could be performed.
Alternatively, the curve could be reconstructed with an in-
creased internal standard concentration.
3.3. Accuracy and precision
The intra- and interassay accuracy and precision are re-
ported in Table 1 for the two QC samples. The accuracy
and precision reported in Table 1 indicate that the method
is extremely precise and also accurate for the concentrations
tested. The ranges of percent relative standard deviation of the
calibrators for the ULOQ (1000 ng/ml) and LLOQ (50 ng/ml)
were 1.5–2.0% and 0.42–8.0%, respectively (n= 3 per day,
for 3 days; data not shown). The ranges of percent deviation
back-calculated from the nominal concentration of the cal-
ibration standards for the ULOQ and LLOQ were 92–94%
and 91–96%, respectively (n= 3 per day, for 3 days; data not
shown).
3.4. Assay selectivity and recovery
Assay selectivity is demonstrated by the absence of inter-
fering peaks in the total ion chromatograph. In Fig. 4, the
ATCA-(TMS)3 peak elutes at approximately 8.76 min and
the blank synthetic urine has little background signal over
the time where ATCA-(TMS)3 elutes from the column. The
ATCA-(TMS)3 peak also elutes during a region where there is
little background signal from the plasma (Fig. 5). Therefore,
the selectivity of the method was adequate for both plasma
and urine. Over twenty samples of blank (non-spiked) syn-
thetic urine were analyzed to demonstrate assay specificity
and selectivity. Although surrogate samples were used for
urine, direct experimental evidence of excellent selectivity in
human plasma was gathered (Fig. 5).
The recovery of ATCA was probed in spiked plasma and
urine samples. The recovery of ATCA was 84% (n= 6) and
100% (n= 6) for synthetic urine and swine plasma samples,
respectively. No matrix effects were observed except when
the post solid-phase extraction column addition of 0.1 M
HC1 was omitted from the analytical procedure. When this
step was omitted, the absolute ATCA-(TMS)3 signal was de-
creased. It should be noted that the internal standard did cor-
rect for this effect. It should also be noted, that the selectivity
and recovery of ATCA from human urine or plasma may be
different than that found during experiments using synthetic
urine and the swine plasma because they are surrogate ma-
trices and can only approximate human urine and plasma.
3.5. Short- and long-term stability
Both the short- and long-term stability of ATCA were
found to be excellent, with Table 2 illustrating that none of
the samples deviated from the control by more than ±9.3%
over the course of all stability experiments. The stability of
ATCA was validated in synthetic urine for 24 h on the bench-
top, through 5 freeze-thaw cycles, and for 3 months at 4,−20,
and−70 ◦C and pH values of 4, 6, and 8. Stability of the TMS
derivatized ATCA was also demonstrated by analysis of the
derivative with increasing periods of storage at room tem-
perature after derivatization. The largest deviation from the
Table 2
Short- and long-term stability of ATCA in synthetic urine
Stability Stability
experiment
Greatest deviation
from control (%)a
Short-termb
Autosamplerc 2.8
Benchtop 4.0
Freeze-thaw 8.9
Long-termb
pH 4, 4 ◦C 9.3
pH 6, 4 ◦C 5.6
pH 8, 4 ◦C −6.8
pH 6, −20 ◦C −5.8
pH 6, −70 ◦C 4.4
a The deviation of each individual sample from the positive control was
calculated and the largest deviation is reported.
b Samples for long-term stability were analyzed for 3 months. Short-term
stability was determined over 20 h for autosampler stability experiments,
24 h for benchtop stability experiments, and over five freeze-thaw cycles.
c Stability of TMS derivatized ATCA at room temperature.
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Table 3
Breakdown of human urine samples of smokers and non-smokers analyzed for ATCA in this study
Urine samples Number of samples ATCA concentration (ng/ml)
Male Female Total Male Female Total
Smokers 8 11 19 115 ± 36 319 ± 284 233 ± 237
Non-smokers 15 6 21 87 ± 46 80 ± 53 85 ± 47
control occurred during the freeze-thaw and the long-term
stability experiments. It should be noted that the largest devi-
ation for the long-term stability samples occurred in the 2nd
month, whereas in the 3rd month, all samples were found to
deviate by less than 5% of the control value. Also, the largest
deviation during the freeze-thaw experiments occurred on the
second freeze-thaw cycle compared with the third through
fifth freeze-thaw cycle of less than 5%. This indicates that
the deviation from the control is not associated with instabil-
ity in ATCA concentrations, but more consistent with random
error in the overall analysis of ATCA.
3.6. Analysis of ATCA in human urine and blood
Applicability of the current analytical method for ATCA
analysis was achieved by analyzing human urine to deter-
mine concentrations of ATCA in non-smoking and smoking
human volunteers. Prior attempts to determine ATCA con-
centrations in non-smokers have failed to determine concen-
trations above the detection limit of the analytical method
[14]. Fig. 4 shows the GC–MS chromatograph of urine in
a male non-smoker without ATCA-d2. A significant ATCA-
(TMS)3 peak is evident in the urine of this subject and is
absent from the non-spiked synthetic urine, which indicates
that endogenous concentrations of ATCA can be determined
by the analytical method presented.
The urine of forty human volunteers was used to deter-
mine concentrations of ATCA in male (23 total) and female
(17 total) smokers and non-smokers. Reported in Table 3 is
a breakdown of the number of volunteers by smoker or non-
smoker and male or female. The mean and standard deviation
of ATCA concentrations analyzed in urine for each group are
also reported in Table 3. It is clear that the mean ATCA con-
centration increases for smokers as opposed to non-smokers
in each individual group. The difference in ATCA concen-
trations between smokers and non-smokers were tested for
significance with a two-tailed t-test. The difference was sig-
nificant to the 99% confidence interval for the pooled data (all
samples, only differentiated by smoker or non-smoker). An
analysis of variance was performed on the data, broken down
into female non-smoker, female smoker, male non-smoker,
and male smoker to determine if there were significant dif-
ferences between the groups indicated. It was determined
that there were significant differences between male smokers
compared with female smokers, male non-smokers compared
with female smokers, and female non-smokers compared
with female smokers. The ability of the analytical method to
determine a significantly elevated concentration of ATCA in
the urine of smokers relative to non-smokers (for the pooled
data) indicates that the analytical method presented will be
able to determine past exposure to higher doses of cyanide.
Although the analytical method can determine significant
differences between urinary ATCA concentrations of smok-
ers versus non-smokers, the large concentration of endoge-
nous ATCA found in urine may present a potential prob-
lem for using this analytical technique to verify exposure
to cyanide. Although this is a potential problem, it is mit-
igated by the fact that other markers of cyanide exposure
also suffer from this problem, and endogenous concentra-
tions for other chemical agent markers have been addressed
in the past [20,21]. Endogenous concentrations of ATCA in
human plasma were found to be below the detection limit
for the method presented (Fig. 5), possibly allowing for the
definitive verification of exposure to cyanide.
4. Conclusions and perspectives
The current GC–MS method to determine ATCA in urine
and plasma is a sensitive and precise analytical method that
shows great promise to augment or replace current analytical
methods to determine past exposure to cyanide. This study
indicates that the method presented can be used with human
urine and plasma samples and can detect endogenous levels
of ATCA in the urine of non-smokers.
Future studies include a broad analysis of ATCA in hu-
man urine of smokers and non-smokers to further evaluate
the analytical method’s ability to determine ATCA in hu-
man urine samples and to establish approximate endogenous
concentrations of ATCA in human urine. These endogenous
concentrations will be used to help determine the validity of
using ATCA as a marker for verification of cyanide exposure.
Other directions include mapping endogenous concentrations
of ATCA in blood, animal tissues, and hair. Also, exposure of
animals to cyanide while monitoring ATCA concentrations
in blood and urine will be used to determine the difference
between endogenous ATCA concentrations and ATCA con-
centrations after exposure to cyanide.
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